Literature DB >> 6746644

Processing of procollagen types III and I in cultured bovine smooth muscle cells.

L Gerstenfeld, J C Beldekas, G E Sonenshein, C Franzblau.   

Abstract

The processing of type III and type I procollagen molecules in cultured bovine aortic smooth muscle cells was investigated. The molecular identities of the processing intermediates of type III and type I procollagen were characterized by analysis of the radioactive collagenous components using mammalian collagenase and pepsin digestions and cyanogen bromide peptide mapping. The results indicate that the processed intermediates for procollagen type III and type I are their respective pC components. Although the processing pathways for both collagen types are the same, data from pulse-chase experiments suggest that the rates at which the processing occurs are different. Type I procollagen is processed more rapidly to its intermediate than is type III procollagen. The type I pC intermediate is almost completely processed to alpha-chains and a significant portion of these fully processed molecules remains in a soluble form even after 11 h. In the same time period, the type III pC intermediate is slowly converted to alpha-chains. Since beta-aminopropionitrile was not employed in these studies, significant accumulation of collagen chains into the insoluble extracellular matrix was observed during the chase period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746644

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  2 in total

1.  Assessment of procollagen processing defects by fibroblasts cultured in the presence of dextran sulphate.

Authors:  J F Bateman; S B Golub
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

2.  Collagen expression, ultrastructural assembly, and mineralization in cultures of chicken embryo osteoblasts.

Authors:  L C Gerstenfeld; S D Chipman; C M Kelly; K J Hodgens; D D Lee; W J Landis
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.